Research ExplorerPublicationsLow level HER2 overexpression is associated with rapid tumor...

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

Standard

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. / Minner, Sarah Jane Pauline; Jessen, Birte; Stiedenroth, Lars; Burandt, Eike Christian; Köllermann, Jens; Mirlacher, Martina; Erbersdobler, Andreas; Eichelberg, Christian; Fisch, Margit; Brümmendorf, Tim; Bokemeyer, Carsten; Simon, Ronald; Steuber, Thomas; Graefen, Markus; Huland, Hartwig; Sauter, Guido; Schlomm, Thorsten.

In: CLIN CANCER RES, Vol. 16, No. 5, 5, 2010, p. 1553-1560.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Minner, SJP, Jessen, B, Stiedenroth, L, Burandt, EC, Köllermann, J, Mirlacher, M, Erbersdobler, A, Eichelberg, C, Fisch, M, Brümmendorf, T, Bokemeyer, C, Simon, R, Steuber, T, Graefen, M, Huland, H, Sauter, G & Schlomm, T 2010, 'Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.', CLIN CANCER RES, vol. 16, no. 5, 5, pp. 1553-1560. <http://www.ncbi.nlm.nih.gov/pubmed/20179235?dopt=Citation>

APA

Minner, S. J. P., Jessen, B., Stiedenroth, L., Burandt, E. C., Köllermann, J., Mirlacher, M., Erbersdobler, A., Eichelberg, C., Fisch, M., Brümmendorf, T., Bokemeyer, C., Simon, R., Steuber, T., Graefen, M., Huland, H., Sauter, G., & Schlomm, T. (2010). Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. CLIN CANCER RES, 16(5), 1553-1560. [5]. http://www.ncbi.nlm.nih.gov/pubmed/20179235?dopt=Citation

Vancouver

Minner SJP, Jessen B, Stiedenroth L, Burandt EC, Köllermann J, Mirlacher M et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. CLIN CANCER RES. 2010;16(5):1553-1560. 5.

Bibtex

@article{90a1829478934deb82370300b7a4bb11,
title = "Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.",
abstract = "The HER2 oncogene is involved in the biology of many different tumor types and serves as a prognostic marker and a therapeutic target in breast cancer. In contrast to breast cancer, studies on Her2 overexpression and gene amplification in prostate cancer have yielded different results. The purpose of this study was to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in prostate cancer.",
keywords = "Humans, Male, Aged, Middle Aged, Prostate-Specific Antigen blood, Immunohistochemistry, Prognosis, Up-Regulation, Neoplasm Recurrence, Local genetics, Gene Amplification, In Situ Hybridization, Fluorescence, Prostatic Neoplasms genetics, Receptor, erbB-2 biosynthesis, Tissue Array Analysis, Tumor Markers, Biological analysis, Humans, Male, Aged, Middle Aged, Prostate-Specific Antigen blood, Immunohistochemistry, Prognosis, Up-Regulation, Neoplasm Recurrence, Local genetics, Gene Amplification, In Situ Hybridization, Fluorescence, Prostatic Neoplasms genetics, Receptor, erbB-2 biosynthesis, Tissue Array Analysis, Tumor Markers, Biological analysis",
author = "Minner, {Sarah Jane Pauline} and Birte Jessen and Lars Stiedenroth and Burandt, {Eike Christian} and Jens K{\"o}llermann and Martina Mirlacher and Andreas Erbersdobler and Christian Eichelberg and Margit Fisch and Tim Br{\"u}mmendorf and Carsten Bokemeyer and Ronald Simon and Thomas Steuber and Markus Graefen and Hartwig Huland and Guido Sauter and Thorsten Schlomm",
year = "2010",
language = "Deutsch",
volume = "16",
pages = "1553--1560",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

AU - Minner, Sarah Jane Pauline

AU - Jessen, Birte

AU - Stiedenroth, Lars

AU - Burandt, Eike Christian

AU - Köllermann, Jens

AU - Mirlacher, Martina

AU - Erbersdobler, Andreas

AU - Eichelberg, Christian

AU - Fisch, Margit

AU - Brümmendorf, Tim

AU - Bokemeyer, Carsten

AU - Simon, Ronald

AU - Steuber, Thomas

AU - Graefen, Markus

AU - Huland, Hartwig

AU - Sauter, Guido

AU - Schlomm, Thorsten

PY - 2010

Y1 - 2010

N2 - The HER2 oncogene is involved in the biology of many different tumor types and serves as a prognostic marker and a therapeutic target in breast cancer. In contrast to breast cancer, studies on Her2 overexpression and gene amplification in prostate cancer have yielded different results. The purpose of this study was to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in prostate cancer.

AB - The HER2 oncogene is involved in the biology of many different tumor types and serves as a prognostic marker and a therapeutic target in breast cancer. In contrast to breast cancer, studies on Her2 overexpression and gene amplification in prostate cancer have yielded different results. The purpose of this study was to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in prostate cancer.

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Prostate-Specific Antigen blood

KW - Immunohistochemistry

KW - Prognosis

KW - Up-Regulation

KW - Neoplasm Recurrence, Local genetics

KW - Gene Amplification

KW - In Situ Hybridization, Fluorescence

KW - Prostatic Neoplasms genetics

KW - Receptor, erbB-2 biosynthesis

KW - Tissue Array Analysis

KW - Tumor Markers, Biological analysis

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Prostate-Specific Antigen blood

KW - Immunohistochemistry

KW - Prognosis

KW - Up-Regulation

KW - Neoplasm Recurrence, Local genetics

KW - Gene Amplification

KW - In Situ Hybridization, Fluorescence

KW - Prostatic Neoplasms genetics

KW - Receptor, erbB-2 biosynthesis

KW - Tissue Array Analysis

KW - Tumor Markers, Biological analysis

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 1553

EP - 1560

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 5

M1 - 5

ER -